ANDA 219136, held by Mankind Pharma. Proparacaine Hydrochloride.
As of Nov 22, 2026, ANDA 219136 (Proparacaine Hydrochloride), held by Mankind Pharma, was first approved by FDA on May 21, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Proparacaine hydrochloride ophthalmic solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical anesthetic prior to surgical operations such as cataract extraction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 21, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Proparacaine Hydrochloride0.5% · solution/drops;ophthalmic | Proparacaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters